top of page
biotech-innovation-drug-pipeline-poseidon.jpg

Pipeline

Phase 3

Phase 2

Target Validation

IND Studies

Phase 1

Phase 2

Phase 3

Target

Colon Cancer

Si44

Target: Xkr8(Oxp)

SMT1

Breast Cancer

Target: iRhom(Dox)

SMT1

SMT

NHL

Target: NTarget

Si44

NSCLC

SMT

Target: mutEGFR

SMT

flowsaber_httpss.mj.runAuw4cZcDglE_httpss.mj.runJnWTZ74hsyo_h_da6f91a5-14f3-449a-a441-b6b5

We built the Trident platform to enable targeting a wide range of cancers – our pipeline is led by POS001, aimed at NSCLC, and followed by other solid tumor indications as well as ALL.

Si44

Colon Cancer

Breast Cancer

44-FREE

NHL

NSCLC

CLL

AML

Multiple

Undisclosed

Phase 3

Phase 2

Phase 1

IND Studies

Target Validation

Target

Target: Xkr8(Oxp)

SMT1

SMT2

SMT

SMT

SMT

SMT

Target: iRhom(Dox)

Target: NTarget

Target: mutEGFR

Target: BTK

Target: BCL2

Target: PD-L1

Target: Combo

SMT

SMT

Colon

Target

PD-L1 x CD3

EGFR x CD3

LGR5 x CD3

TAA x CD3

IND Enabling

Lead
Optimization

Discovery

Phase 1

POS001

Indication: NSCLC

POS002

Indication: GBM

POS003

Indication: Gastric Cancer

POS004

Indication: ALL

POS001

NSCLC

PD-L1 x CD3

EGFR x CD3

GBM

POS002

LGR5 x CD3

Gastric Cancer

POS003

TAA x CD3

ALL

POS004

IND Enabling

Lead
Optimization

Discovery

Target

Indication

Asset

Phase 1

t-cell-solid-tumor-engager.jpg
bottom of page